Literature DB >> 34550772

Simultaneous or Prior Activation of Intrahepatic Type I Interferon Signaling Leads to Hepatitis B Virus Persistence in a Mouse Model.

Shi Zou1, Yanqin Du1,2, Shunmei Huang1,3, Shuilin Sun4, Dongliang Yang1, Jun Wu1, Mingfa Chen5, Xiaoli Yang1, Sumeng Li1, Yingshan Chen6, Meihong Han1, Jia Li1, Qing Yu1, Elisabeth Littwitz-Salomon2, Hongming Huang1, Mirko Trilling2, Shi Liu7, Rongjuan Pei6, Jia Liu1, Baoju Wang1, Xin Zheng1, Mengji Lu2, Ulf Dittmer2.   

Abstract

It remains controversial how interferon (IFN) response contributes to hepatitis B virus (HBV) control and pathogenesis. A previous study identified that hydrodynamic injection (HI) of type I IFN (IFN-I) inducer polyinosinic-poly(C) [poly(I·C)] leads to HBV clearance in a chronic HBV mouse model. However, recent studies have suggested that premature IFN-I activation in the liver may facilitate HBV persistence. In the present study, we investigated how the early IFN-I response induces an immunosuppressive signaling cascade and thus causes HBV persistence. We performed HI of the plasmid adeno-associated virus (pAAV)/HBV1.2 into adult BALB/c mice to establish an adult acute HBV replication model. Activation of the IFN-I signaling pathway following poly(I·C) stimulation or murine cytomegalovirus (MCMV) infection resulted in subsequent HBV persistence. HI of poly(I·C) with the pAAV/HBV1.2 plasmid resulted in not only the production of IFN-I and the anti-inflammatory cytokine interleukin-10 (IL-10) but also the expansion of intrahepatic regulatory T cells (Tregs), Kupffer cells (KCs), and myeloid-derived suppressor cells (MDSCs), all of which impaired the T cell response. However, when poly(I·C) was injected at day 14 after the HBV plasmid injection, it significantly enhanced HBV-specific T cell responses. In addition, interferon-alpha/beta receptor (IFNAR) blockade rescued T cell response by downregulating IL-10 expression and decreasing Treg and KC expansion. Consistently, Treg depletion or IL-10 blockade also controlled HBV replication. IMPORTANCE IFN-I plays a double-edged sword role during chronic HBV infection. Here, we identified that application of IFN-I at different time points causes contrast outcomes. Activation of the IFN-I pathway before HBV replication induces an immunosuppressive signaling cascade in the liver and consequently caused HBV persistence, while IFN-I activation post HBV infection enhances HBV-specific T cell responses and thus promotes HBV clearance. This result provided an important clue to the mechanism of HBV persistence in adult individuals.

Entities:  

Keywords:  chronic hepatitis B; interleukin 10; regulatory T cells; type I interferon

Mesh:

Substances:

Year:  2021        PMID: 34550772      PMCID: PMC8610600          DOI: 10.1128/JVI.00034-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro.

Authors:  Jia Liu; Min Jiang; Zhiyong Ma; Kirsten K Dietze; Gennadiy Zelinskyy; Dongliang Yang; Ulf Dittmer; Joerg F Schlaak; Michael Roggendorf; Mengji Lu
Journal:  J Immunol       Date:  2013-11-13       Impact factor: 5.422

2.  Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes.

Authors:  Zhenhua Zhang; Martin Trippler; Catherine I Real; Melanie Werner; Xufeng Luo; Stefan Schefczyk; Thekla Kemper; Olympia E Anastasiou; Yvonne Ladiges; Juergen Treckmann; Andreas Paul; Hideo A Baba; Lena Allweiss; Maura Dandri; Guido Gerken; Heiner Wedemeyer; Joerg F Schlaak; Mengji Lu; Ruth Broering
Journal:  Hepatology       Date:  2020-07-11       Impact factor: 17.425

3.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.

Authors:  Bertram Bengsch; Bianca Martin; Robert Thimme
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

4.  Type I interferon-enhanced IL-10 expression in human CD4 T cells is regulated by STAT3, STAT2, and BATF transcription factors.

Authors:  Umeshree Govender; Béatrice Corre; Yasmine Bourdache; Sandra Pellegrini; Frédérique Michel
Journal:  J Leukoc Biol       Date:  2017-02-27       Impact factor: 4.962

5.  Different antiviral effects of IFNα and IFNβ in an HBV mouse model.

Authors:  Yun Zhou; Sheng Li; Zongsheng Tang; Chunli Xu; Shunmei Huang; Jun Wu; Ulf Dittmer; Julia Dickow; Kathrin Sutter; Mengji Lu; Dongliang Yang; Jingjiao Song
Journal:  Immunobiology       Date:  2016-11-08       Impact factor: 3.144

Review 6.  Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure.

Authors:  Jinhong Chang; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2015-07-20       Impact factor: 5.970

7.  Temporal analysis of early immune responses in patients with acute hepatitis B virus infection.

Authors:  Claire Dunn; Dimitra Peppa; Pooja Khanna; Gaia Nebbia; Meleri Jones; Nathan Brendish; R Monica Lascar; David Brown; Richard J Gilson; Richard J Tedder; Geoffrey M Dusheiko; Michael Jacobs; Paul Klenerman; Mala K Maini
Journal:  Gastroenterology       Date:  2009-07-07       Impact factor: 22.682

8.  Genomic analysis of the host response to hepatitis B virus infection.

Authors:  Stefan Wieland; Robert Thimme; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-20       Impact factor: 11.205

9.  Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus.

Authors:  Kirsten Schneider; Andrea Loewendorf; Carl De Trez; James Fulton; Antje Rhode; Heather Shumway; Sukwon Ha; Ginelle Patterson; Klaus Pfeffer; Sergei A Nedospasov; Carl F Ware; Chris A Benedict
Journal:  Cell Host Microbe       Date:  2008-02-14       Impact factor: 21.023

10.  Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells.

Authors:  Laura J Pallett; Upkar S Gill; Alberto Quaglia; Linda V Sinclair; Maria Jover-Cobos; Anna Schurich; Kasha P Singh; Niclas Thomas; Abhishek Das; Antony Chen; Giuseppe Fusai; Antonio Bertoletti; Doreen A Cantrell; Patrick T Kennedy; Nathan A Davies; Muzlifah Haniffa; Mala K Maini
Journal:  Nat Med       Date:  2015-05-11       Impact factor: 53.440

View more
  1 in total

Review 1.  Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.

Authors:  Yanqin Du; Jun Wu; Jia Liu; Xin Zheng; Dongliang Yang; Mengji Lu
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.